Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$166.91 USD
-2.73 (-1.61%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $166.81 -0.10 (-0.06%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRL 166.91 -2.73(-1.61%)
Will CRL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River Q2 Earnings Preview: What's in Store for the Stock?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
Other News for CRL
CRL Crosses Below Key Moving Average Level
Charles River (CRL) Explores New Partnership for Funding Opportunities
Charles River, BioTech Social to pursue crowdfunding partnership
Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership | CRL Stock News
ClearBridge Growth Fund Q2 2025 Commentary